Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PLTR +15.8%, COHR +11.7%, VRNS +7%, CHX +6.3%, PINC +6.3% (also completes strategic review process), SPOT +5.5%, BP +5.3%, AUDC +5.2%, LLY +4.8%, FI +3.7%, TM +3.5%, PNM +3.4%, NXPI +3%, GEHC +2.8%, ATHM +2.7%, BRBR +2.6%, CNC +2.3%, DCPH +2.3%, DD +2.1%, ARMK +2%, J +1.8%, ACM +1.6%, LIN +1.6%, CEIX +1.6%, VRTX +1.4% (announces positive results), SKY +1.3%, CBT +1.3%, CARR +1.3%, HIMX +1.1%, WTW +1.1%, AME +1.1%, GBDC +1%, UMC +1% (Jan revs), KKR +1%, SPG +0.9%
Other news:
- VLRS +5% (January traffic)
- ARVN +3.1% (Arvinas and Pfizer (PFE) announce that the U.S. FDA has granted Fast Track designation for the investigation of vepdegestrant for monotherapy in the treatment of adults with estrogen receptor positive/human growth epidermal growth factor 2 negative)
- RPRX +2.6% (discloses MorphoSys (MOR) details following Novartis (NVS) acquisition news)
- MOR +2% (to be acquired by Novartis AG)
- INCY +0.8% (asset purchase agreement with MorphoSys)
- OXY +0.7% (Berkshire Hathaway's (BRK.A) Warren Buffett bought another 4302324 shares worth approx. $245.9 mln)
Analyst comments:
- LI +8.1% (upgraded to Buy from Hold at Deutsche Bank)
- LPRO +3.7% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- UPS +1.9% (upgraded to Buy from Neutral at UBS)
- TSN +0.7% (upgraded to Neutral from Underperform at BofA Securities)